UCB Provides Update on U.S. FDA Review of the Biologics License Application for Bimekizumab

Brussels (Belgium), 26th June 2023– UCB, a global biopharmaceutical company, today announced that the Biologics License Application (BLA) for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis remains under...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news